Abstract
Chimeric antigen receptor (CAR) T cell therapy of solid cancer remains below expectations; adding cytokine help through IL-18 has shown remarkable efficacy in first clinical trials. As IL-18 is also...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have